BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21651979)

  • 1. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
    Chiang MC; Chern Y; Juo CG
    Biochim Biophys Acta; 2011 Sep; 1812(9):1111-20. PubMed ID: 21651979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
    Chiang MC; Chern Y; Huang RN
    Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
    Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
    Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells.
    Chiang MC; Cheng YC; Nicol CJ; Lin KH; Yen CH; Chen SJ; Huang RN
    Exp Cell Res; 2015 Nov; 338(2):183-93. PubMed ID: 26362846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
    Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
    Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGC-1alpha, a new therapeutic target in Huntington's disease?
    McGill JK; Beal MF
    Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
    Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
    Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
    Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
    Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
    Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
    Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
    Chandra A; Sharma A; Calingasan NY; White JM; Shurubor Y; Yang XW; Beal MF; Johri A
    Hum Mol Genet; 2016 Jun; 25(11):2269-2282. PubMed ID: 27008868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease.
    Chiang MC; Chen HM; Lee YH; Chang HH; Wu YC; Soong BW; Chen CM; Wu YR; Liu CS; Niu DM; Wu JY; Chen YT; Chern Y
    Hum Mol Genet; 2007 Mar; 16(5):483-98. PubMed ID: 17213233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
    Quintanilla RA; Jin YN; Fuenzalida K; Bronfman M; Johnson GVW
    J Biol Chem; 2008 Sep; 283(37):25628-25637. PubMed ID: 18640979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
    Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
    Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
    Tsunemi T; Ashe TD; Morrison BE; Soriano KR; Au J; Roque RA; Lazarowski ER; Damian VA; Masliah E; La Spada AR
    Sci Transl Med; 2012 Jul; 4(142):142ra97. PubMed ID: 22786682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
    Hathorn T; Snyder-Keller A; Messer A
    Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
    Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
    Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells.
    Lee HJ; Su Y; Yin PH; Lee HC; Chi CW
    Anticancer Res; 2009 Dec; 29(12):5057-63. PubMed ID: 20044617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
    Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
    J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.